{"id":"NCT00974974","sponsor":"Impax Laboratories, LLC","briefTitle":"A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).","officialTitle":"A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2011-01","completion":"2011-03","firstPosted":"2009-09-11","resultsPosted":"2016-01-14","lastUpdate":"2020-08-11"},"enrollment":471,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"IPX066","otherNames":["ER CD-LD"]},{"type":"DRUG","name":"IR CD-LD","otherNames":["immediate-release carbidopa-levodopa"]}],"arms":[{"label":"IPX066","type":"EXPERIMENTAL"},{"label":"IR CD-LD","type":"ACTIVE_COMPARATOR"}],"summary":"This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease.","primaryOutcome":{"measure":"Percentage of \"Off\" Time During Waking Hours at End of Study","timeFrame":"22 weeks","effectByArm":[{"arm":"IPX066","deltaMin":23.82,"sd":14.91},{"arm":"IR CD-LD (Active Comparator)","deltaMin":29.79,"sd":15.81}],"pValues":[{"comp":"OG001","p":"<.0001"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":73,"countries":["United States","Canada","France","Germany","Poland","Romania","Spain","Ukraine"]},"refs":{"pmids":["30425824","23485610"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":201},"commonTop":["Fall","Insomnia","nausea","Oedema Peripheral","Upper Respiratory Tract Infection"]}}